CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-10-24 | CELGENE CORP /DE/ 10% owner | Purchase | +800,150 | $14.00 | $11.2M | 4,834,980 |
| 2016-10-24 | CELGENE CORP /DE/ 10% owner | Conversion · Series B Preferred Shares | −4,034,830 | 0 | ||
| 2016-10-24 | George Simeon Director | Conversion | +2,942,560 | 2,942,560 | ||
| 2016-10-24 | George Simeon Director | Conversion | +211,567 | 3,154,127 | ||
| 2016-10-24 | George Simeon Director | Purchase | +66,500 | $14.00 | $931K | 3,220,627 |
| 2016-10-24 | George Simeon Director | Conversion · Series A-3 Preferred Shares | −2,942,560 | 0 | ||
| 2016-10-24 | George Simeon Director | Conversion · Series B Preferred Shares | −211,567 | 0 | ||
| 2016-10-24 | GLAXOSMITHKLINE PLC 10% owner | Conversion | +2,942,560 | 2,942,560 | ||
| 2016-10-24 | GLAXOSMITHKLINE PLC 10% owner | Conversion | +211,567 | 3,154,127 | ||
| 2016-10-24 | GLAXOSMITHKLINE PLC 10% owner | Purchase | +66,500 | $14.00 | $931K | 3,220,627 |
| 2016-10-24 | GLAXOSMITHKLINE PLC 10% owner | Conversion · Series A-3 Preferred Shares | −2,942,560 | 0 | ||
| 2016-10-24 | GLAXOSMITHKLINE PLC 10% owner | Conversion · Series B Preferred Shares | −211,567 | 0 | ||
| 2016-10-24 | COLES N ANTHONY Director | Grant or award | +35,000 | $14.00 | $490K | 70,000 |
| 2016-10-24 | COLES N ANTHONY Director | Grant or award | +35,000 | $14.00 | $490K | 70,000 |
| 2016-10-24 | Versant Venture Capital IV, L.P. 10% owner | Grant or award | +95,596 | $14.00 | $1.3M | 4,104,045 |
| 2016-10-24 | Versant Venture Capital IV, L.P. 10% owner | Grant or award | +602 | $14.00 | $8K | 24,334 |
| 2016-10-24 | Versant Venture Capital IV, L.P. 10% owner | Grant or award | +60,219 | $14.00 | $843K | 2,443,803 |
| 2016-10-24 | Versant Venture Capital IV, L.P. 10% owner | Grant or award | +4,583 | $14.00 | $64K | 185,987 |
| 2016-10-24 | Hadley Harbor Master Investors (Cayman) L.P. 10% owner | Conversion | +744,380 | 744,380 | ||
| 2016-10-24 | Hadley Harbor Master Investors (Cayman) L.P. 10% owner | Conversion · Series B Convertible Preferred Shares | −744,380 | 0 |
Page 73 of 74 · 1,471 trades